Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P22891
UPID:
PROZ_HUMAN
Alternative names:
-
Alternative UPACC:
P22891; A6NMB4; Q15213; Q5JVF5; Q5JVF6
Background:
Vitamin K-dependent protein Z plays a crucial role in blood coagulation, acting as a regulatory factor in the intricate balance of hemostasis. It functions by binding thrombin and enhancing its association with phospholipid vesicles, alongside inhibiting the coagulation protease factor Xa in a complex with SERPINA10, calcium, and phospholipids. This protein's unique mechanism underscores its importance in the coagulation cascade.
Therapeutic significance:
Understanding the role of Vitamin K-dependent protein Z could open doors to potential therapeutic strategies. Its pivotal function in regulating blood coagulation presents an opportunity for developing novel treatments for coagulation disorders.